NCGI
PHAT icon

Next Century Growth Investors’s Phathom Pharmaceuticals PHAT Stock Holding History

Next Century Growth Investors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-393,774
Closed -$6.53M – 129
2025
Q4 		$6.53M Buy
+393,774
New +$5.62M 0.45% 69

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Next Century Growth Investors's PHAT Position: Q1 2026 in Review

Next Century Growth Investors sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 393,774 shares — an estimated $6.53M sold.

Next Century Growth Investors first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $6.53M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Next Century Growth Investors reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Next Century Growth Investors sold 393,774 Phathom Pharmaceuticals shares in Q1 2026, an estimated $6.53M.
  • Next Century Growth Investors first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Next Century Growth Investors's Phathom Pharmaceuticals position peaked at $6.53M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Next Century Growth Investors's 13F filing for Q1 2026, filed 14 May 2026.